Thanks. I'm still holding a smaller position in this one (actually my smallest holding). I still don't trust how the stock will react to the P2 data for the lead drug next Q. I'm typically a bit wary when companies have multiple next-gen versions of a lead drug right behind in development as it just makes me wonder if the lead drug won't be sufficient. Keeping a bit of dry powder to potentially add big if there is any significant sell-off.